GSK-1674330A

GSK-1674330A is a virus-like particle (VLP) therapeutic and shared antigen vaccine developed by GSK for the prevention of infection with human papillomavirus (HPV), specifically targeting types 16, 18, 33, and 58. It is designed as an immunostimulant to elicit an immune response against oncogenic HPV types associated with cervical cancer and other neoplasms. The mechanism of action involves stimulating the immune system to recognize and respond to the L1 capsid proteins of these HPV types. The drug was evaluated in phase I clinical trials for safety and immunogenicity in healthy female subjects but has since been discontinued from further development[1][2][3].

Other names

Human papillomavirus (types 16, 18, 33, 58) L1 virus-like particle vaccineHuman papillomavirus (types 16, 18, 33, 58) L1 VLP vaccine